Clarity AI and CDP announce environmental data product partnership
Clarity AI, a leading sustainability technology platform, and CDP, the non-profit which runs the global environmental disclosure system, have today announced a new partnership focused on jointly developing and bringing to market new products for financial institutions to measure and act on their environmental impact.
Clarity AI’s extensive global client network manages tens of trillions of assets and counts on the Clarity AI platform to turn raw data into products that are easily consumable, including scores and analytics for integration in third-party platforms.
Through this partnership, CDP data will be used in Clarity AI's Net Zero tool, which supports financial institutions in managing and reporting their Net Zero alignment, in line with the industry-backed Net Zero Investment Framework (NZIF). CDP’s fund rating Climetrics – a free-to-search database of global ETFs and funds rated on their environmental performance, will also be calculated by Clarity AI.
"CDP brings deep expertise in collecting and cleaning raw climate data, and we are thrilled to work together to ensure our clients are receiving the best signposts on their paths to Net Zero,” said Patricia Pina, Head of Product Research & Innovation at Clarity AI.
Laurent Babikian, Global Director Data Products and Distribution CDP said, “As CDP holds the world’s largest self-reported environmental dataset, this partnership will ensure Clarity AI clients have access to the most comparable, science-based and comprehensive environmental data available. When greenwashing in ESG must be tackled with robust data, we look forward to working with Clarity AI to ensure their clients have the best possible products for building Net Zero portfolios and rapidly align their investment flows with the 1.5°C goal of the Paris agreement and our planet’s limits.”
The partnership between Clarity AI and CDP aligns with the missions of both organizations to build a sustainable economy and bring societal impact to markets. The two companies are committed to helping clients chart a path to a more sustainable world by measuring and acting on their environmental impact.
About Clarity AI
Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, organizations, and consumers. As of January 2023, Clarity AI’s platform analyzes more than 70,000 companies, 360,000 funds, 198 countries and 199 local governments – the broadest data coverage in the market with up to 13 times more than any other player – and delivers data and analytics for investing, corporate research, benchmarking, consumer ecommerce and reporting. Clarity AI has offices in North America, Europe and the Middle East, and its investor client network manages tens of trillions of assets, while its consumer partnerships allow it to be part of millions of daily ecommerce transactions and to reach hundreds of millions of consumers at over 400,000 merchants.
About CDP
CDP is a global non-profit that runs the world’s environmental disclosure system for companies, cities, states and regions. Founded in 2000 and working with more than 680 financial institutions with over $130 trillion in assets, CDP pioneered using capital markets and corporate procurement to motivate companies to disclose their environmental impacts, and to reduce greenhouse gas emissions, safeguard water resources and protect forests. Nearly 20,000 organizations around the world disclosed data through CDP in 2022, including more than 18,700 companies worth half of global market capitalization, and over 1,100 cities, states and regions. Fully TCFD aligned, CDP holds the largest environmental database in the world, and CDP scores are widely used to drive investment and procurement decisions towards a zero carbon, sustainable and resilient economy. CDP is a founding member of the Science Based Targets initiative, We Mean Business Coalition, The Investor Agenda and the Net Zero Asset Managers initiative.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005768/en/
Contact information
Clarity AI Media Contact
Edelman
clarityAI@edelmansmithfield.com
CDP Media Contact
Joshua Snodi
joshua.snodin@cdp.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 16:01:00 EET | Press release
Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ
Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 16:00:00 EET | Press release
Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as enterprises and AI developers alike seek a better, more predictable alternative to the hyperscalers.” Wasabi disrupted the cloud storage model in 2017 wi
Armis Secures Italy’s Primary Public Healthcare Provider for the City of Naples as Cyber Threats Increase13.1.2026 15:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced that ASL Napoli 1 Centro, Italy’s primary public healthcare provider for the City of Naples, is securing its attack surface using Armis Centrix™, the Armis Cyber Exposure Management Platform. Prior to working with Armis, ASL Napoli 1 Centro did not have the tools or capabilities to monitor physical and virtual assets in real time, which posed a challenge for its security and compliance. Armis Centrix™ was deployed with a clear goal: to provide ASL Napoli 1 Centro with a comprehensive, real-time view of its connected biomedical inventory and the associated risks to the overall environment. “Time-to-value was practically immediate; Armis began delivering valuable information as soon as the system was activated and connected to our internal network,” said Fulvio Paone, Director of the ICT and Digital Transformation Unit at ASL Napoli 1 Centro. “Armis has given us visibility into a critical area. This isn’t just about
Opengear Introduces CM8000 and OM1300: Two New Paths to Network Resilience as Outages Surge13.1.2026 15:00:00 EET | Press release
Opengear, a Digi International company (NASDAQ, DGII), today announced two new additions to its Network Resilience Platform: the CM8000 Series and the OM1300 Series. These next generation devices deliver compact, flexible, and automation-ready out-of-band infrastructure designed for a time when outages are increasing and distributed sites continue to scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113807672/en/ Opengear Introduces CM8000 and OM1300: Two New Paths to Network Resilience as Outages Surge According to Opengear research, 84 percent of CIOs and CISOs have experienced a rise in outages over the past two years. The CM8000 Series and OM1300 Series were purpose-built to ensure that IT teams maintain access and control even when the production network is unavailable. The two series provide complementary approaches: CM8000 Series A serial-first recovery platform with integrated power control for core branches,
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 15:00:00 EET | Press release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom